Oratray Announces Equity Investment From Greyhill's Oral Care Fund

The investment backs Oratray's dental tray platform — the fluoride tray in the FDA 510(k) pathway, plus the new Vitamin E Wellness Tray.



Oratray announces an equity investment from Greyhill's Oral Care Fund to advance its prefilled dental tray platform, including the fluoride tray now progressing through the FDA 510(k) pathway.

MIAMI, FL, UNITED STATES, September 15, 2026 /EINPresswire.com/ -- Oratray Announces Equity Investment from Greyhill's Oral Care Fund

Investment backs Oratray's prefilled dental tray delivery platform, with its prescription fluoride tray as the first product advancing through the FDA 510(k) pathway

Oratray Inc., a Delaware-based developer of a prefilled dental tray drug/device delivery platform for oral health, today announced that Greyhill Ventures Oral Care Fund I LP, Greyhill's dedicated oral care technology fund, has made an equity investment in the company. The investment closed in March 2026. Terms of the investment, including the amount, were not disclosed.

Since the investment closed, Oratray has added a second product to the platform, the Oratray Vitamin E Wellness Tray, a cosmetic/wellness SKU designed to support gum health, ease comfort after teeth whitening, support gum comfort after dental procedures, and promote overall oral wellness. Oratray expects the Vitamin E Wellness Tray to enter production by the end of 2026, with commercial launch targeted for the first quarter of 2027, with the regulated fluoride tray to follow on 510(k) clearance.

The Vitamin E Wellness Tray is the second product built on Oratray's core platform: a flexible, mouthguard-shaped tray fitted with easy-to-burst gel packs that release an active formulation across the teeth and gums when the user bites down. Oratray's first regulated product built on the same platform, a prescription fluoride tray designed to address tooth sensitivity through dentin tubule occlusion, is advancing through the FDA's Class II / 510(k) pathway under an active pre-submission. The fluoride tray has not been cleared by the FDA and is not available for sale in

the United States.

“We're glad to have Greyhill's Oral Care Fund as an investor in Oratray. Their focus on oral care technology aligns closely with what we're building, and we are glad to have their support as we build out the platform.”

— Fernando Volante, CEO and Co-Founder, Oratray
Greyhill's Oral Care Fund invests in early-stage companies developing transformative technologies within the dental healthcare ecosystem. It is led by Faizal Javer, who co-founded and exited a technology company acquired by a Fortune 100 buyer and has personally backed companies from their earliest rounds that reached unicorn valuations, and by venture partner Dr. Rustom Appoo, EVP, Clinical Operations at a dental support organization (DSO) and owner and operator of his own dental clinics. Its limited partners and advisors include practicing clinicians, and founders and executives drawn from leading distributors, DSOs and medical device companies across North America.

“Oratray's platform approach to oral care delivery is exactly the kind of innovation our Oral Care Fund was built to support. We backed the platform and its first application in fluoride, on the view that the same delivery format can carry other actives over time. Oral care is a category where the clinical case keeps strengthening while the delivery model stands still, and a prefilled tray that works in a single bite is simple enough to reach the settings where care is hardest to deliver. There is regulatory work ahead and we are glad to be backing this team through it.”
— Faizal Javer, Managing Partner, Greyhill Oral Care Fund

Oratray has reported growing commercial interest in its platform, including an order from Teledentistry.com valued in the millions of dollars annually, with deliveries to begin following FDA 510(k) clearance, and a letter of intent from Oral Genome for its Vitamin E Wellness Tray. The company holds granted U.S. patents covering its delivery system and has been granted corresponding patent protection in Europe, with an international PCT filing also on file.

Oratray was co-founded by Fernando Volante, CEO, who holds a law degree and an MBA and has previously built and exited two businesses, and Dr. Martin Fernandez Feo, COO and CPO, a DMD graduate of the Boston University School of Dental Medicine. Dr. Vilas Sastry DMD, CEO of Teledentistry.com, is an advisor to and investor in Oratray.

Fernando Volante
Oratray Inc
+1 786-360-6657
email us here
Visit us on social media:
LinkedIn
Instagram

This press release can be viewed online at: https://www.einpresswire.com/article/942168009

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.